Gastroenterologists Unlikely To Use Celltrion/hospira’s Infliximab Biosimilar Due To Lack Of Clinical Data In Inflammatory Bowel Disease

If you have any questions or comments about this page please contact pressreleases@worldnow.com . SOURCE BioTrends Research Group Rheumatologists Expect More Extensive Clinical Trials for Biosimilars than Gastroenterologists, According to a New Report from BioTrends Research Group EXTON, Penn., Sept. 30, 2013 /PRNewswire/ — BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that the majority of surveyed gastroenterologists do not expect to prescribe an infliximab biosimilar, such as Celltrion’s Remsima, in their Crohn’s disease (CD) or ulcerative colitis (UC) patients that has not been clinically tested in inflammatory bowl diseases. The Biosimilars Advisory Service report entitled Physician Perspectives on Pegylated IFN-a and TNF-a Inhibitors in Immune and Infectious Disease provides analysis of survey results from over 90 gastroenterologists, as well as more than 90 rheumatologists in the United States and Europe. The report finds that over 70 percent of surveyed gastroenterologists would not use biosimilar infliximab in CD or UC patients if the clinical trial had only been conducted in rheumatoid arthritis patients. Only a minority of survey respondents believe that indication extrapolation is an overall good idea. The report also finds that surveyed rheumatologists are similarly cautious about indication extrapolation, but most biosimilars of TNF-alpha inhibitors under development are being studied in rheumatoid arthritis patients. This strategy by biosimilar manufacturers could help to alleviate rheumatologists’ concerns about prescribing these biosimilar TNF-alpha inhibitors, but this study also reveals that rheumatologists would prefer a longer treatment duration and more patients to be included in biosimilar clinical trials compared with their gastroenterology counterparts. “The concept of indication extrapolation is particularly relevant to prescribers of TNF-alpha inhibitors because of the breadth of indications that these biologics are used in,” said Biosimilars Research Director Kate Keeping. “The first biosimilar TNF-alpha inhibitor that gastroenterologists will have access to, Celltrion/Hospira’s Inflectra (infliximab), has not been clinically tested in CD or UC patients, which will likely limit uptake in these patients, at least until direct clinical evidence is available.” The Biosimilars Advisory Service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilars space. The service includes quarterly webinars detailing major developments, analyst insight addressing key market changes and opportunities, therapeutic area-specific primary research and forecasting modules. About BioTrends Research Group BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit http://www.bio-trends.com . BioTrends is a Decision Resources Group company. About Decision Resources Group Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions.

click here to investigate http://www.8newsnow.com/story/23566476/gastroenterologists-unlikely-to-use-celltrionhospiras-infliximab-biosimilar-due-to-lack-of-clinical-data-in-inflammatory-bowel-disease

Gastroenterologists Unlikely To Use Celltrion/Hospira’s Infliximab Biosimilar Due To Lack Of Clinical Data In Inflammatory Bowel Disease

The Biosimilars Advisory Service report entitled Physician Perspectives on Pegylated IFN-a and TNF-a Inhibitors in Immune and Infectious Disease provides analysis of survey results from over 90 gastroenterologists, as well as more than 90 rheumatologists in the United States and Europe. The report finds that over 70 percent of surveyed gastroenterologists would not use biosimilar infliximab in CD or UC patients if the clinical trial had only been conducted in rheumatoid arthritis patients. Only a minority of survey respondents believe that indication extrapolation is an overall good idea. The report also finds that surveyed rheumatologists are similarly cautious about indication extrapolation, but most biosimilars of TNF-alpha inhibitors under development are being studied in rheumatoid arthritis patients. This strategy by biosimilar manufacturers could help to alleviate rheumatologists’ concerns about prescribing these biosimilar TNF-alpha inhibitors, but this study also reveals that rheumatologists would prefer a longer treatment duration and more patients to be included in biosimilar clinical trials compared with their gastroenterology counterparts. “The concept of indication extrapolation is particularly relevant to prescribers of TNF-alpha inhibitors because of the breadth of indications that these biologics are used in,” said Biosimilars Research Director Kate Keeping. “The first biosimilar TNF-alpha inhibitor that gastroenterologists will have access to, Celltrion/Hospira’s Inflectra (infliximab), has not been clinically tested in CD or UC patients, which will likely limit uptake in these patients, at least until direct clinical evidence is available.” The Biosimilars Advisory Service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilars space. The service includes quarterly webinars detailing major developments, analyst insight addressing key market changes and opportunities, therapeutic area-specific primary research and forecasting modules. About BioTrends Research Group BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit http://www.bio-trends.com . BioTrends is a Decision Resources Group company. About Decision Resources Group Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry.

find out here now http://finance.yahoo.com/news/gastroenterologists-unlikely-celltrion-hospiras-infliximab-150000156.html

Advertisements

Why International Medical Students Deserve A Place In Australian Hospitals

This diversification of supply has proven extremely challenging for Australia. The 2006 census shows just 53% of IMGs secured medical employment in Australia in their first five years of residence (across all immigration categories). Doctors from English-speaking background countries moved seamlessly into work, while Commonwealth-Asian doctors fared reasonably. Outcomes were poor, by contrast, for many birthplace groups. Just 6% of doctors from China found medical employment within five years, along with 23% from Vietnam and 31% from Eastern Europe. Australia is short 182 intern places. SydneyUni Employment access is significantly better for IMGs selected through the 457 visa temporary sponsored pathway. From 2005-06 to 2010-11 17,910 doctors were sponsored as temporary 457 visa migrants to pre-arranged jobs, with a 99% immediate employment rate. From 2004-05 to 2010-11, an additional 2,790 IMGs were admitted through the permanent General Skilled Migration category. But not all passed the Australian Medical Council examinations, which are a requirement for unconditional registration in Australia. From 1978 to 2010, 82% of candidates passed the MCQ (the standard theoretical examination), typically on their first or second attempt, along with 85% of clinical candidates. But overall AMC completion rates were just 43%, since many choose not to persist with the process.

her response http://theconversation.com/why-international-medical-students-deserve-a-place-in-australian-hospitals-10261

Telstra invests in electronic health record specialists IP Health

It extracts information in real time from a hospitals existing paper or electronic databases, enabling information to appear to derive from a single source for simultaneous sharing. Telstra Ventures Managing Director, Matthew Koertge, said the investment in IP Health aligned to Telstras strategy of developing new growth businesses and would build capability in Telstras Health portfolio. This investment fits with Telstras new health business unit by complementing our existing mobility and hosting solutions and expanding our offering to hospitals. IP Health will be an important asset as we continue to build capability in this area, Mr Koertge said. There are more than 1300 hospitals in Australia, most using multiple systems. This new partnership will help IP Health accelerate its growth by combining our strong and trusted brand, our technology know-how and scale with an innovative software solution. IP Healths Verdi software operates on top of existing systems, is modestly priced, quick to implement and compatible with all hospital systems. Patient information is available on mobile devices for clinicians to use anywhere which is important for specialists who work across multiple hospitals and practices, he said. IP Health CEO, Ashley Renner, said the Verdi solution enables doctors to access and update patient information and treatments, greatly reducing risks and improving response times. Many doctors are called upon out-of-hours to respond to patient needs. Verdi enables those doctors to have the patients full history at their fingertips. This means that if a doctor is called at home for an emergency they could monitor a live read of a patients ECG on their iPad, cross check their pathology results from a number of laboratories and make a recommendation to the nurse on call. Having this information on hand means that more accurate decisions can be made more quickly and at the end of the day that saves lives, Mr Renner said. There are currently more than 5000 clinicians using Verdi at the Peter MacCallum Cancer Centre and satellites in Victoria, and the Mater Hospital group in Queensland. Director, Division of Cancer Medicine at the Peter MacCallum Cancer Centre in Melbourne, Professor John Zalcberg, OAM, said that Verdi made life much easier and saved time for busy clinicians using the medical record to monitor their patients. Everything is available and trackable.

at yahoo http://www.whatech.com/members-news/practice-management-software/15634-telstra-invests-in-electronic-health-record-specialists-ip-health

Health Workforce Australia Report Gives The Nod To Physician Assistants

One thing the report alludes to is that the acceptance of the Physician Assistant role is based on the level of understanding. The greater the respondent understood the role of the Physician Assistant that more likely it was to be accepted. What does this report mean for Australian Physician Assistants? Firstly, it will stimulate a great deal of discussion, both positive and negative. The report clearly outlines positive impact that the physician assistant will have on the Australian health workforce and the overwhelming support of the rural and remote health sector. To date, most opposition to the Physician Assistant role has been based on a poor understanding of this model of healthcare, which this report confirms. The contents of the report provide a clear and detailed description of the role of Physician Assistant, which should lead to a greater understanding of the position. So, what is the next step? Well the next step is in fact already happening and as can be seen from the recent events in Tasmania, there is a desire in some states to commence the introduction of a Physician Assistant. Whilst the work being conducted in individual Australian states should continue, the Physician Assistant should also be considered at the national level. This report echoes the sentiments of the Australian College of Rural and Remote Medicine (ACRRM) that the profession should be registered nationally under AHPRA, and likely administered by the Australian Medical Board.

look at more info http://blogs.crikey.com.au/croakey/2012/08/24/health-workforce-australia-report-gives-the-nod-to-physician-assistants/

Australian Doctors, Scientists Wage War On Alternative Medicine

AlternativeMedSS-Post.jpg

In 1997 Kevin Sorbo, known for his starring role in the television series Hercules, felt a searing pain in his left shoulder during a workout. Thinking it was a strain, he went to see his chiropractor, who manipulated his neck for treatment. Several days later the actor suffered a stroke and a recent article in Neurology Now links the aneurysm with the actions of his chiropractor. The article is currently used as reference material by a prominent group of Australian doctors, medical researchers, and scientists who are trying to curb what they refer to as pseudosciences, like branches of chiropractic practice, right at their root: the universities where they are taught. Friends of Science in Medicine (FSM) already has 450 members. They include Ian Frazer, the inventor of the cervical cancer vaccine, and Sir Gustav Nossal, a renowned immunologist. Among their group, 50 are international and they too hope to snuff out what they refer to as modern-day quackery. The group has written a letter to all of Australia’s university vice-chancellors asking them to: “Reverse the trend which sees government-funded tertiary institutions offering courses in the health care sciences that are not underpinned by convincing scientific evidence.” The questionable courses include homeopathy, iridology, reflexology, Chinese herbal medicine, chiropractic, naturopathy, and aromatherapy, some of which are taught at 18 of 39 Australian universities. “A university is supposed to be a bastion of good science, but their reputation is let down by teaching something like homeopathy,” said John Dwyer, a founding member of FSM and emeritus professor of medicine at the University of New South Wales. But in Australia, just like in the United States, alternative medicine is a billion-dollar industry. Even though the country has a decent health care system — a publication from the Commonwealth Fund looked at seven countries and Australia’s health care system was ranked third, while the U.S. was ranked last — the interest in natural health seems to be booming. According to data from the National Herbalists Association of Australia (NHAA), 70 percent of Australians use complementary medicine.

original site http://www.theatlantic.com/health/archive/2012/03/australian-doctors-scientists-wage-war-on-alternative-medicine/253342/

Australian Doctors Get Right to Assist Suicide

Nickson, 54 and single, a former theater company director who found himself a spokesman for legislation that has turned the Northern Territory of Australia into the first jurisdiction in the world to allow doctors to take the lives of terminally ill patients who wish to die. After the bill was passed last spring in the territorial parliament, Mr. Nickson said: “I felt relief. I can get on with living and know that I can be helped if the time comes.” The legislation is history-making, with the first terminally ill patients expected to make use of the law later this year, and it has drawn an outcry from the Australian Medical Association, church leaders and anti-euthanasia groups. Under the law, a patient whose illness has been diagnosed as terminal by two doctors can ask for death, usually by pill or lethal injection, to put an end to suffering. At least one of the doctors must have a background in psychiatry, and a patient must wait at least nine days — a “cooling-off period” — before the request can be met. Opponents of the bill say it could turn Darwin, the capital of the Northern Territory, into the world’s suicide capital, with patients coming from around the world to this sparsely populated corner of Australia in the knowledge that someone will help them to die. Although individual doctors have come forward to say they would be willing to carry out the law, major doctors’ groups have opposed the bill because, they say, it is a violation of the Hippocratic Oath for doctors to be put in the position of deciding to end a life. Margaret Tighe, chairwoman of Right to Life Australia, said the bill would encourage families to put pressure on aging or mentally ill relatives literally to sign away their lives. “The people who are most vulnerable and least able to speak up for themselves are the ones who will lose their lives in this,” Mrs. Tighe said. “People who don’t think that’s the case are being terribly naive.” The Roman Catholic Archdiocese in Sydney, the nation’s largest city, said in a statement that the bill “in no way resolves the most fundamental issue of all — and that is that no one in society ought to have the right to end someone else’s life.” While euthanasia is legal to some degree in several nations, no place has gone quite so far as the Northern Territory, an area twice the size of Texas with a population of 160,000, about half of them in Darwin. It is Australia’s last frontier.

straight from the source http://www.nytimes.com/1995/07/28/world/australian-doctors-get-right-to-assist-suicide.html

Canadian Doctors Still Make Dramatically Less Than U.s. Counterparts: Study

How much sugar is in Nutella? Canadian doctor decodes what’s in the hazelnut spread

health-policy professors concluded in one of the most detailed looks yet at the differences in doctor compensation between nations. The U.K. also pays its surgeons more than Canada, while both it and Germany better compensate primary-care doctors, like family physicians and pediatricians, the comparison of six industrialized countries suggests. Canada should not ignore the wage gap, as a sudden shortage of certain specialists in the States could trigger a drain from here, said Dr. John Haggie, president of the Canadian Medical Association. Canada saw a net loss of doctors to the U.S. in the 1990s, as provinces instituted doctor pay caps and tried to rein-in fee increases as a way to corral health costs. But Dr. Haggie voiced no particular envy Tuesday at the statistics just published in the journal Health Affairs , saying that factors other than money influence where doctors settle, including for some the appeal of Canadas universal, government-funded health system. A good salary package is an attractor, its a magnet but it doesnt always have the same effect at the other end when youre trying to retain people, said Dr. Haggie. The system in which (physicians) work is part of the attraction of working here. That migration to the U.S. has reversed in the last few years, with a small net influx of MDs from south of the border as incomes rose here, according to statistics and the accounts of medical recruitment agencies.

check out the post right here http://news.nationalpost.com/2011/09/14/canadian-doctors-still-make-dramatically-less-than-u-s-counterparts-study/

If Nutella is a morning breakfast staple in your kitchen, you should probably stop reading this story. A Canadian doctor is sounding the warning bells about the chocolate hazelnut spread, showing viewers in a new video just how much sugar goes into two tablespoons. Story continues below His answer: five hazelnuts, some skim milk powder, whey powder and cocoa powder, about a half teaspoon of palm oil and 5.5 teaspoons of sugar, which is an amazing feat,Dr. Yoni Freedhoff adds. Make no mistake, Nutella is spreadable candy. It is not healthy, breakfast does not love it. You might love it, but this does not help to make a nutritious breakfast fun, it helps to make a nutritious breakfast non-nutritious, Freedhoff said. Hes a leading obesity expert and physician at the University of Ottawa and Bariatric Medical Institute. The video was posted Monday in his blog, Weighty Matters . Its already been shared more than 3,200 times . Watch the video here. To put it in perspective, Freedhoff stacks five Oreo cookies on top of a piece of toast thats the equivalent of the amount of sugar in the spoonfuls of Nutella. His findings are based on the ad suggesting there are 94 hazelnuts in a jar and the nutrition facts panel on the product. (Global News graphic) There are literally no name frosted icings that have fewer calories and less sugar than Nutella does spoon for spoon, Freedhoff said.

pop over to this web-site http://globalnews.ca/news/874931/how-much-sugar-is-in-nutella-canadian-doctor-decodes-whats-in-the-hazelnut-spread/